EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer | Future Oncology
Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo
Frontiers | Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1) - Annals of Oncology
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
Fulvestrant - LiverTox - NCBI Bookshelf
Breast Cancer Update - Lynn Sage 2001
Pure Antiestrogens - Selective Estrogen Receptor Modulators. Antonio Cano
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action | British Journal of Cancer
Mode of action of estradiol and fulvestrant. AF1: activation function... | Download Scientific Diagram
Fulvestrant | SpringerLink
Breast Cancer Update - Lynn Sage 2001
Figure 2 from ICI 182,780 (Fulvestrant™) – the first oestrogen receptor down-regulator – current clinical data | Semantic Scholar
The molecular mechanism for the pure steroidal ERα antagonist,... | Download Scientific Diagram
Estrogen alpha receptor antagonists for the treatment of breast cancer: a review | BMC Chemistry | Full Text
Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review - Li - 2019 - Cancer Medicine - Wiley Online Library
Ribociclib Improves Survival in Advanced Breast Cancer - NCI
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspect
Fulvestrant-Induced Cell Death and Proteasomal Degradation of Estrogen Receptor α Protein in MCF-7 Cells Require the CSK c-Src Tyrosine Kinase | PLOS ONE
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer | Breast Cancer Research | Full Text
Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review. - Abstract - Europe PMC
